Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (25)
Matthew Ho, Saurabh Zanwar & Jonas Paludo. (2023)
Chimeric antigen receptor
T‐cell
therapy in hematologic malignancies: Successes, challenges, and opportunities
. European Journal of Haematology.
Crossref
Crossref
Rui X, Meidan W, Gongqiang W, Longyi Z, Xiaoxia W, Wei C & Chenhui W. (2023) Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review. Frontiers in Oncology 13.
Crossref
Crossref
Hanwen Zhang, Tenzin Passang, Sruthi Ravindranathan, Ramireddy Bommireddy, Mohammad Raheel Jajja, Lily Yang, Periasamy Selvaraj, Chrystal M. Paulos & Edmund K. Waller. (2023) The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy. Frontiers in Immunology 14.
Crossref
Crossref
Dawn Swan, Philip Murphy, Siobhan Glavey & John Quinn. (2023) Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Cancers 15:6, pages 1819.
Crossref
Crossref
Xinping Cao, Xin Jin, Xiaomei Zhang, Paudel Utsav, Yi Zhang, Ruiting Guo, Wenyi Lu & Mingfeng Zhao. (2023) Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies. Current Treatment Options in Oncology 24:3, pages 184-211.
Crossref
Crossref
Stephanie Lakritz, Peter A. Forsberg, Daniel W. Sherbenou & Tomer M. Mark. (2022) Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis. Clinical Case Reports 10:9.
Crossref
Crossref
Igor Radanovic, Naomi Klarenbeek, Robert Rissmann, Geert Jan Groeneveld, Emilie M. J. van Brummelen, Matthijs Moerland & Jacobus J. Bosch. (2022) Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. Frontiers in Oncology 12.
Crossref
Crossref
Chen-Lu Geng, Jun-Yi Chen, Tian-Yu Song, Jae Hyung Jung, Min Long, Min-Fang Song, Tong Ji, Byung Soh Min, Jin Gu Lee, Bo Peng, Yi-Sheng Pu, Hong-Jie Fan, Piliang Hao, Qi Zhou, Eui-Cheol Shin & Yong Cang. (2022) Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. Cell Chemical Biology 29:8, pages 1260-1272.e8.
Crossref
Crossref
Murali Janakiram, Nivedita Arora, Veronika Bachanova & Jeffrey S. Miller. (2022) Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy 28:2, pages 61-69.
Crossref
Crossref
Sophia Stock, Anna-Kristina Kluever, Stefan Endres & Sebastian Kobold. (2022) Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines 10:2, pages 307.
Crossref
Crossref
Jian-Qing Mi, Jie Xu, Jianfeng Zhou, Weili Zhao, Zhu Chen, J. Joseph Melenhorst & Saijuan Chen. (2021) CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine 15:6, pages 783-804.
Crossref
Crossref
Egor V. Batorov, Tatiana A. Aristova, Natalia V. Pronkina, Vera V. Sergeevicheva, Svetlana A. Sizikova, Galina Y. Ushakova, Ekaterina Y. Shevela, Alexander A. Ostanin & Elena R. Chernykh. (2021) Highly proliferative and functional PD-1+ and TIM-3+ T cells are transiently increased in multiple myeloma following autologous hematopoietic stem cell transplantation. International Immunopharmacology 100, pages 108093.
Crossref
Crossref
Criselle D'Souza, H. Miles Prince & Paul J. Neeson. (2021) Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. Frontiers in Immunology 12.
Crossref
Crossref
Alissa Visram, Surendra Dasari, Emilie Anderson, Shaji Kumar & Taxiarchis V. Kourelis. (2021) Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer Journal 11:3.
Crossref
Crossref
Anne Marit Sponaas, Anders Waage, Esten N. Vandsemb, Kristine Misund, Magne Børset, Anders Sundan, Tobias Schmidt Slørdahl & Therese Standal. (2021) Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?. Frontiers in Immunology 12.
Crossref
Crossref
Timothy M. Schmidt & Natalie S. Callander. (2020) Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma. Journal of the National Comprehensive Cancer Network 18:12, pages 1720-1729.
Crossref
Crossref
Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C. Jones, Wendy Curtis, Patrick Carlson, Timothy G. Johnstone, David Kugler, Ronald J. Hause, Yue Jiang, Lindsey Wimberly, Christopher R. Clouser, Heidi K. Jessup, Blythe Sather, Ruth A. Salmon & Michael O. Ports. (2019) Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide. Molecular Cancer Therapeutics 18:12, pages 2246-2257.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Giulia Di Lullo, Magda Marcatti, Silvia Heltai, Cristina Tresoldi, Anna Maria Paganoni, Claudio Bordignon, Fabio Ciceri & Maria Pia Protti. (2019) Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma. Frontiers in Immunology 9.
Crossref
Crossref
Lorenzo Galluzzi, Stefani Spranger, Elaine Fuchs & Alejandro López-Soto. (2019) WNT Signaling in Cancer Immunosurveillance. Trends in Cell Biology 29:1, pages 44-65.
Crossref
Crossref
Karel Fostier, Jo Caers, Nathalie Meuleman, Katrijn Broos, Jurgen Corthals, Kris Thielemans, Rik Schots & Brenda De Keersmaecker. (2018) Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget 9:29, pages 20476-20489.
Crossref
Crossref
Brigitte Neuber, Jingying Dai, Wjahat A. Waraich, Mohamed H.S. Awwad, Melanie Engelhardt, Michael Schmitt, Sergej Medenhoff, Mathias Witzens-Harig, Anthony D. Ho, Hartmut Goldschmidt & Michael Hundemer. (2017) Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28− T-cells. Oncotarget 8:58, pages 98200-98214.
Crossref
Crossref
Angelika Muchowicz, Malgorzata Wachowska, Joanna Stachura, Katarzyna Tonecka, Magdalena Gabrysiak, Dominika Wołosz, Zofia Pilch, Witold W. Kilarski, Louis Boon, Tomasz J. Klaus & Jakub Golab. (2017) Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice. European Journal of Cancer 83, pages 19-27.
Crossref
Crossref
Yahiya Y. Syed. (2017) Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT. Drugs 77:13, pages 1473-1480.
Crossref
Crossref
Leo Rasche, Niels Weinhold, Gareth J. Morgan, Frits van Rhee & Faith E. Davies. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treatment Reviews 55, pages 190-199.
Crossref
Crossref